Abstract:
:Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate side chain extending from C14 of the tricyclic core. Lefamulin inhibits bacterial protein synthesis by binding to the 50S bacterial ribosomal subunit in the peptidyl transferase center (PTC). The pleuromutilin tricyclic core binds to a pocket close to the A site, while the C14 side chain extends to the P site causing a tightening of the rotational movement in the binding pocket referred to as an induced-fit mechanism. Lefamulin displays broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria as well as against atypical bacteria that commonly cause CABP. Pleuromutilin antibiotics exhibit low rates of resistance development and lack cross-resistance to other antimicrobial classes due to their unique mechanism of action. However, pleuromutilin activity is affected by mutations in 23S rRNA, 50S ribosomal subunit proteins rplC and rplD, ATP-binding cassette (ABC)-F transporter proteins such as vga(A), and the methyltransferase cfr. The pharmacokinetic properties of lefamulin include: volume of distribution (Vd) ranging from 82.9 to 202.8 L, total clearance (CLT) of 19.5 to 21.4 L/h, and terminal elimination half-life (t1/2) of 6.9-13.2 h; protein binding of lefamulin is high and non-linear. The oral bioavailability of lefamulin has been estimated as 24% in fasted subjects and 19% in fed subjects. A single oral dose of lefamulin 600 mg administered in fasted patients achieved a maximum plasma concentration (Cmax) of 1.2-1.5 mg/L with a time of maximum concentration (Tmax) ranging from 0.8 to 1.8 h, and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 8.5-8.8 mg h/L. The pharmacodynamic parameter predictive of lefamulin efficacy is the free plasma area under the concentration-time curve divided by the minimum inhibitory concentration (fAUC24h/MIC). Lefamulin efficacy has been demonstrated using various animal models including neutropenic murine thigh infection, pneumonia, lung infection, and bacteremia. Lefamulin clinical safety and efficacy was investigated through a Phase II clinical trial of acute bacterial skin and skin structure infection (ABSSSI), as well as two Phase III clinical trials of CABP. The Phase III trials, LEAP 1 and LEAP 2 established non-inferiority of lefamulin to moxifloxacin in both oral and IV formulations in the treatment of CABP. The United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada have each approved lefamulin for the treatment of CABP. A Phase II clinical trial has been completed for the treatment of ABSSSI, while the pediatric program is in Phase I. The most common adverse effects of lefamulin include mild-to-moderate gastrointestinal-related events such as nausea and diarrhea. Lefamulin represents a safe and effective option for treating CABP in cases of antimicrobial resistance to first-line therapies, clinical failure, or intolerance/adverse effects to currently used agents. Clinical experience and ongoing clinical investigation will allow clinicians and antimicrobial stewardship programs to optimally use lefamulin in the treatment of CABP.
journal_name
Drugsjournal_title
Drugsauthors
Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JAdoi
10.1007/s40265-020-01443-4subject
Has Abstractpub_date
2020-11-28 00:00:00eissn
0012-6667issn
1179-1950pii
10.1007/s40265-020-01443-4pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...
journal_title:Drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40265-018-0925-3
更新日期:2018-06-01 00:00:00
abstract::The rationale for an arginine vasopressin (argipressin) infusion was put forward after it was discovered that patients in shock states might have an endogenous arginine vasopressin deficiency. Subsequently, several investigations impressively demonstrated that arginine vasopressin can successfully stabilise haemodynam...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363030-00001
更新日期:2003-01-01 00:00:00
abstract::For many years now a treatment mitigating the debilitating effects of jet lag has been sought. Rapid travel across time zones leads, in most people, to temporary symptoms, in particular poor sleep, daytime alertness and poor performance. Mis-timed circadian rhythms are considered to be the main factor underlying jet-l...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0973-8
更新日期:2018-09-01 00:00:00
abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600322-00004
更新日期:1986-01-01 00:00:00
abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199100423-00004
更新日期:1991-01-01 00:00:00
abstract::Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550050-00006
更新日期:1995-11-01 00:00:00
abstract::Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363100-00004
更新日期:2003-01-01 00:00:00
abstract::The role of serotonin in the pathogenesis of hypertension is not clear. Serotonin is produced by the enterochromaffin cells of the gut; the greater part of this is metabolised in the liver and lungs and nearly all of the remainder is taken up by the platelets. Consequently, circulating levels of serotonin are extremel...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800361-00011
更新日期:1988-01-01 00:00:00
abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500491-00008
更新日期:1995-01-01 00:00:00
abstract::Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding (approximately 99%) and rapid first-pass clearance furth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868060-00009
更新日期:2008-01-01 00:00:00
abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11317670-000000000-00000
更新日期:2009-10-01 00:00:00
abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666020-00002
更新日期:2006-01-01 00:00:00
abstract::Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243030-00006
更新日期:1992-03-01 00:00:00
abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0558-3
更新日期:2016-04-01 00:00:00
abstract::25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198529020-00003
更新日期:1985-02-01 00:00:00
abstract::Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550040-00004
更新日期:1995-10-01 00:00:00
abstract::Oesophageal cancer is the eighth most common cancer diagnosed worldwide, with almost half a million new cases diagnosed each year. Despite improvements in surgical and radiotherapy techniques and refinements of chemotherapeutic regimens, long-term survival, even from localized oesophageal cancer, remains poor. Surgica...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11585460-000000000-00000
更新日期:2011-03-26 00:00:00
abstract::Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After severa...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700341-00014
更新日期:1987-01-01 00:00:00
abstract::In a double-blind study, 128 patients with essential hypertension, refractory to beta-blocker monotherapy, were randomised to 1 of 4 treatment groups. Felodipine 2.5 mg twice daily, 5mg twice daily, 10mg twice daily or matched placebo twice daily were administered in addition to the beta-blocker for 4 weeks. Mean supi...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700343-00023
更新日期:1987-01-01 00:00:00
abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01320-0
更新日期:2020-06-01 00:00:00
abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0396-8
更新日期:2015-05-01 00:00:00
abstract::This article reviews the development and pharmacokinetics of a number of new dosage formulations (e.g. transdermal patches and buccal tablets) and new active substances (e.g. isosorbide 5-mononitrate) which have recently been introduced to overcome some of the problems inherent in conventional formulations of organic ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700334-00006
更新日期:1987-01-01 00:00:00
abstract::The clinical and bacteriological efficacy and adverse reactions of ofloxacin vs trimethoprim-sulphamethoxazole were investigated in a double-blind, randomised study in 250 female patients (125 in each group) with acute, uncomplicated lower urinary tract infections. The dosages of ofloxacin and trimethoprim-sulphametho...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700341-00022
更新日期:1987-01-01 00:00:00
abstract::A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutica...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01112-1
更新日期:2019-05-01 00:00:00
abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-018-1009-0
更新日期:2018-11-01 00:00:00
abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00013
更新日期:1988-01-01 00:00:00
abstract::Pentamidine is an aromatic diamidine derivative which has become one of the standard therapies for Pneumocystis carinii pneumonia (PCP), particularly in patients with acquired immunodeficiency syndrome (AIDS). However, with parenteral administration of the drug there is a high risk of toxicity. Inhaled pentamidine pro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039050-00008
更新日期:1990-05-01 00:00:00
abstract::Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767030-00008
更新日期:2007-01-01 00:00:00
abstract::Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis. It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the const...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199651030-00007
更新日期:1996-03-01 00:00:00
abstract::Potassium channel openers or agonists represent a novel new class of compounds in the treatment of a range of cardiovascular disorders, particularly angina pectoris and hypertension. Nicorandil is the only clinically available potassium channel opener with antianginal effects, and with comparable efficacy and tolerabi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161120-00002
更新日期:2001-01-01 00:00:00